Internal Reference Number: FOI_7983
Date Request Received: 05/06/2024 00:00:00
Date Request Replied To: 19/06/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on biologic medicines in Gastroenterology
Request Category: Companies
| Question Number 1: I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions: Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Etrasimod • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 1: • Adalimumab – Humira 8 • Adalimumab Biosimilar 91 • Etrasimod 0 • Filgotinib 18 • Golimumab <5 • Infliximab – Remicade <5 • Infliximab Biosimilar 81 • Mirikizumab 0 • Ozanimod 0 • Risankizumab <5 • Tofacitinib <5 • Upadacitinib 13 • Ustekinumab 87 • Vedolizumab 79 | |
| Question Number 2: Could you please provide the numbers of patients treated for Crohn’s Disease in the last 3 months with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilars • Golimumab • Infliximab - Remicade • Infliximab Biosimilars • Risankizumab • Upadacitinib • Ustekinumab • Vedolizumab | |
| Answer To Question 2: • Adalimumab – Humira 7 • Adalimumab Biosimilars 71 • Golimumab 0 • Infliximab – Remicade <5 • Infliximab Biosimilars 53 • Risankizumab <5 • Upadacitinib 11 • Ustekinumab 64 • Vedolizumab 32 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
